ERBB2 and urinary bladder carcinoma: Prior clinical trials investigating Her2-targeted therapies in MIBC have been limited by their use of only FISH and IHC for patient selection17, 18, 19, and by the absence of Her2 cut-off levels validated specifically for bladder cancer.